中文English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R

留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

慢性乙型肝炎抗病毒治疗专家共识

引用本文:
Citation:

慢性乙型肝炎抗病毒治疗专家共识

详细信息
  • 中图分类号: R512.62

Expert consensus on antiviral therapy for chronic hepatitis B


  • [1] 中华医学会肝病学分会、感染病学分会.慢性乙型肝炎防治指南[J].中华肝脏病杂志, 2005, 13 (12) :881-891.
    [2]Liaw YF, Leung N, Kao JH, et al.Asian-Pacific consensus state-ment on the management of chronic hepatitis B:a2008update[J].Hepatol Int, 2008, 2 (3) :263-283.
    [3]European Association For The Study of The Liver.EASL Clinical Practice Guidelines:management of chronic hepatitis B[J].J Hepa-tol, 2009, 50 (2) :227-242.
    [4]Lok AS, McMahon BJ.Chronic hepatitis B:update2009[J].Hep-atology, 2009, 50 (3) :661-662.
    [5] 2006年全国人群乙肝血清流行病学调查结果[R].卫生部疾病控制专题新闻发布会:http://www.gov.cn/xwfb/2008-04/21/content-950425.htm.
    [6]McMahon BJ.The natural history of chronic hepatitis B virus infec-tion[J].Hepatology, 2009, 49:S45-S55.
    [7]Lok AS, Heathcote EJ, Hoofnagle JH.Management of hepatitis B:2000--summary of a workshop[J].Gastroenterology, 2001, 120 (7) :1828-1853.
    [8]Lok AS.Mc, Mahon BJ.Chronic hepatiits B[J].Hepatology, 2007, 45:507-539.
    [9]Zoulim F, Perrillo R.Hepatitis B:reflections on the current ap-proach to antiviral therapy[J].J Hepatol, 2008, 48 (Suppl1) :S2-S19.
    [10]Perrillo RP, Schiff ER, Davis GL, et al.Arandomized, controlled trial of interferon alfa-2b alone and after prednisone withdrawal for the treatment of chronic hepatitis B[J].N Engl J Med, 1990, 323 (5) :295-301.
    [11]Wong DK, Cheung AM, O'Rourke K, et al.Effect of alpha-in-terferon treatment in patients with hepatitis B e antigen-positive chronic hepatitis B[J].A meta analysis.Ann Intern Med, 1993, 119 (4) :312-323.
    [12]Bonino F, Marcellin P, Lau GK, et al.Predicting response to peginterferon alpha-2a, lamivudine and the two combined for HBeAg-negative chronic hepatitis B[J].Gut, 2007, 56 (5) :699-705.
    [13]Fried MW, Piratvisuth T, Lau GKK, et al.HBeAg and hepatitis B virus DNAas outcome predictors during therapy with peginterferon al-fa-2a for HBeAg positive chronic hepatitis B[J].Hepatology, 2008, 47 (2) :428-434.
    [14]Perrillo RP, Lai CL, LiawYF, et al.Predictors of HBeAg loss after lamivudine treatment for chronic hepatitis B[J].Hepatology, 2002, 36 (1) :186-194.
    [15]Flink HJ, van Zonneveld M, Hansen BE, et al.HBV99-01Study Group.Treatment with Peginterferon alpha-2b for HBeAg-positive chronic hepatitis B:HBsAg loss is associated with HBVgen-otype[J].Am J Gastroenterol, 2006, 101 (2) :297-303.
    [16]Lampertico P, Del Ninno E, Vigano M, et al.Long-termsuppres-sion of hepatitis B e antigen-negative chronic hepatitis B by24-month interferon therapy[J].Hepatology, 2003, 37 (4) :756-763.
    [17]Cooksley WG, Piratvisuth T, Lee SD, et al.Peginterferon alpha-2a (40kDa) :an advance in the treatment of hepatitis B e antigen-positive chronic hepatitis B[J].J Viral Hepat, 2003, 10 (4) :298-305.
    [18]Lok AS, Lai CL, Leung N, et al.Long-term safety of lamivudine treatment in patients with chronic hepatitis B[J].Gastroenterology, 2003, 125 (6) :1714-1722.
    [19]Hadziyannis SJ, Papatheodoridis GV, Dimou E, et al.Efficacy of long-term lamivudine monotherapy in patients with hepatitis B e an-tigen-negative chronic hepatitis B[J].Hepatology, 2000, 32 (4) :847-851.
    [20]Fontana RJ, Hann HW, Perrillo RP, et al.Determinants of early mortality in patients with decompensated chronic hepatitis B treated with antiviral therapy[J].Gastroenterology, 2002, 123 (3) :719-727.
    [21]Song BC, Suh DJ, Lee HC, et al.Hepatitis B e antigen seroconver-sion after lamivudine therapy is not durable in patients with chronic hepatitis B in Korea[J].Hepatology, 2000, 32 (4) :803-806.
    [22]Lee KM, Cho SW, Kim SW, et al.Effect of virological response on post-treatment durability of lamivudine-induced HBeAg seroconve-rsion[J].J Viral Hepat, 2002, 9 (3) :208-212.
    [23]Liaw YF, Leung NW, Chang TT, et al.Effects of extended lamivu-dine therapy in Asian patients with chronic hepatitis B.Asia Hepati-tis Lamivudine Study Group[J].Gastroenterology, 2000, 119 (1) :172-180.
    [24]Leung NW, Lai CL, Chang TT, et al.Extended lamivudine treat-ment in patients with chronic hepatitis B enhances hepatitis B e anti-gen seroconversion rates:results after3years of therapy[J].Hepa-tology, 2001, 33 (6) :1527-1532.
  • 加载中
计量
  • 文章访问数:  2794
  • HTML全文浏览量:  4
  • PDF下载量:  1129
  • 被引次数: 0
出版历程
  • 出版日期:  2010-02-20
  • 分享
  • 用微信扫码二维码

    分享至好友和朋友圈

目录

    /

    返回文章
    返回